Suven Life Sciences Ltd (Suven) has received product patents from Macau and New Zealand for its new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases, or central nervous systems (CNS), and these patents are valid through 2032.
The granted claims of the patents are from the mechanism of action include the class of selective 5-HT4 compounds and H3 inverse agonist compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, major depressive disorder (MDD), Parkinson and Schizophrenia.
With these new patents, Suven has a total of nine granted patents from Macau and 25 granted patents from New Zealand.
